Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Schinke on Talquetamab in Multiple Myeloma

June 30th 2023

Carolina D. Schinke, MD, discusses updated findings from the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

June 27th 2023

Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.

Induction Therapy Regimens for Transplant-Eligible NDMM

June 27th 2023

Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.

Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma

June 26th 2023

Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shares the long-term findings from the pivotal CARTITUDE-1 trial, and highlights future directions for CAR T-cell therapy in this disease.

Dr Munshi on the Future of CAR T-Cell Therapy in Multiple Myeloma

June 23rd 2023

Nikhil C. Munshi, MD, discusses potential future directions for ciltacabtagene autoleucel and other CAR T-cell therapies in patients with multiple myeloma.

Dr Bal on the Safety Profile of BMS-986393 in R/R Multiple Myeloma

June 22nd 2023

Susan Bal, MD, discusses the toxicity profile of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, according to findings from a phase 1 trial.

Dr Bal on the Investigation of BMS-986393 in R/R Multiple Myeloma

June 21st 2023

Susan Bal, MD, discusses updated safety and efficacy data from the dose-escalation and dose-expansion portions of phase 1 trial of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in patients with relapsed/refractory multiple myeloma.

Dr Costa on MRD-Modulated Post-ASCT Quadruplet Induction in Newly Diagnosed Multiple Myeloma

June 21st 2023

Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.

NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

June 20th 2023

Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.

What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

June 20th 2023

Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.

FDA Places Clinical Hold on BCMA-Directed Modified CAR T-Cell Therapy in Multiple Myeloma

June 20th 2023

The FDA has placed a hold on the clinical program for the investigational new drug CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Patel on the Efficacy of Ide-Cel in Patients With High-Risk R/R Multiple Myeloma

June 19th 2023

Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.

Dr Lee on the Investigation of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

June 15th 2023

Hans C. Lee, MD, discusses the investigation of the BCMA x CD3 bispecific antibody linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Dholaria on Updated Efficacy Data From the TRIMM-2 Trial of Talquetamab and Daratumumab in R/R Multiple Myeloma

June 12th 2023

Bhagirathbhai Dholaria, MBBS, discusses additional 10-month follow-up data from the phase 1 TRIMM-2 trial of subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma.

Cilta-Cel Demonstrates Long-Term PFS, Safety in R/R Multiple Myeloma

June 11th 2023

Administration of a single infusion of ciltacabtagene autoleucel prolonged progression-free survival, generated sustained responses, and continued to demonstrate a manageable safety profile in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to final results from the phase 1b/2 CARTITUDE-1 study.

Dr Munshi on the Final Results of the CARTITUDE-1 Trial of Cilta-Cel in R/R Myeloma

June 11th 2023

Nikhil C. Munshi, MD, discusses the efficacy data from the final analysis of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr Mohty on Extended Follow-up Data from MagnetisMM-3 With Elranatamab in R/R Myeloma

June 10th 2023

Mohamad Mohty, MD, PhD, discusses extended follow-up from cohort A of the phase 2 MagnetisMM-3 trial of elranatamab in patients with relapsed/refractory multiple myeloma.

DaraVCD Elicits Responses in Multiple Myeloma With Extramedullary Disease

June 9th 2023

The combination of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone, elicited a complete response (CR) rate of 40% and a CR or better rate of 43% in patients with multiple myeloma presenting with extramedullary disease.

Daratumumab Maintenance Is Safe, Feasible After Salvage Transplant in Multiple Myeloma

June 9th 2023

Daratumumab maintenance therapy with or without pomalidomide provided a tolerable and feasible treatment option after salvage hematopoietic stem cell transplantation in patients with relapsed multiple myeloma.

Teclistamab Data Show Sustained Benefit in Relapsed/Refractory Multiple Myeloma

June 9th 2023

Teclistamab continued to elicit deep and durable responses in patients with relapsed/refractory multiple myeloma, irrespective of being triple-class refractory, daratumumab-refractory, or refractory to last line of therapy.